Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 3/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.55 |
| ▸ | JAK3 | P52333 | 9/20 | 0.54 |
| ▸ | JAK1 | P23458 | 8/20 | 0.54 |
| ▸ | TYK2 | P29597 | 5/20 | 0.54 |
| ▸ | JAK2 | O60674 | 5/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 4/20 | 0.48 |
| ▸ | CDC7 | O00311 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124144 | 0.92 | JAK2 (0.58) | GLO1ALKJAK3JAK1TYK2 | |
| SCHEMBL2121008 | 0.89 | GLO1 (0.69) | GLO1ALKJAK3JAK1TYK2 | |
| SCHEMBL2124535 | 0.81 | GLO1 (0.56) | GLO1ALKJAK3JAK1TYK2 | |
| SCHEMBL2122745 | 0.79 | GLO1 (0.56) | GLO1ALKJAK3JAK1TYK2 | |
| SCHEMBL1038863 | 0.79 | SYK (0.58) | GLO1ALKJAK3JAK1TYK2 | |
| SCHEMBL2122486 | 0.78 | JAK2 (0.53) | GLO1ALKJAK3JAK1TYK2 | |
| SCHEMBL2122267 | 0.77 | ALK (0.78) | GLO1ALKJAK3JAK1TYK2 | |
| SCHEMBL2123417 | 0.77 | ALK (0.67) | GLO1ALKJAK3JAK1TYK2 | |
| SCHEMBL601598 | 0.77 | GLO1 (0.54) | GLO1JAK2CDK19SYKGSK3A | |
| SCHEMBL2123175 | 0.75 | GLO1 (0.63) | GLO1ALKJAK3JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | claimed |
| EP-2443106-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2012-04-25 | — | — | EP | claimed |
| WO-2010146133-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-23 | — | — | WO | claimed |
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2443106-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010146133-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | ZAP70, JAK3, JAK2 | GLO1 3371/4885ALK 233/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.